Teva shares fall after ending Phase 2 MSA drug trial

Teva will discontinue the Phase 2 TOPAS-MSA trial of emrusolmin in adults with multiple system atrophy after an independent data monitoring committee recommended stopping on a prespecified interim futility analysis. That analysis found a low probability of meeting the primary efficacy endpoint if continued and identified no safety concerns. The randomized, double-blind, placebo-controlled study was set for about 350 participants on emrusolmin 300 mg or placebo for about 48 weeks. Emrusolmin is developed with MODAG GmbH; it received FDA Orphan Drug designation for MSA in 2022 and Fast Track in September 2025. MSA affects about 40,000 people in the U.S., EU, and Japan, with about 6,000 new cases a year. Teva said the decision applies only to TOPAS-MSA and is not final for the broader emrusolmin program. It plans to analyze the trial data and open-label extension findings. Eric Hughes, Teva's global R&D head and chief medical officer, said the company is disappointed by the interim outcome but remains committed to learning from the data. Shares fell more than 3% in premarket trading, with one report putting the drop at 3.30% to $40.70. Coverage shows no contested facts on the halt or safety finding. Next steps for the wider program remain unresolved pending Teva's review.